Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.50 |
| ▸ | VDR | P11473 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069220 | 0.90 | VDR (0.49) | MAPTSMN1; SMN2SREBF1VDRPGR | |
| SCHEMBL7264353 | 0.90 | MAPT (0.57) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| SCHEMBL14489385 | 0.82 | VDR (0.53) | VDR | |
| SCHEMBL14880276 | 0.81 | MAPT (0.52) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| SCHEMBL24572466 | 0.81 | VDR (0.59) | MAPTSMN1; SMN2SREBF1VDRPGR | |
| SCHEMBL7263451 | 0.81 | VDR (0.59) | MAPTSMN1; SMN2SREBF1VDRPGR | |
| SCHEMBL18476082 | 0.80 | VDR (0.57) | MAPTSMN1; SMN2SREBF1VDRPGR | |
| SCHEMBL14806585 | 0.80 | VDR (0.54) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| SCHEMBL14806651 | 0.80 | VDR (0.54) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| SCHEMBL9000917 | 0.80 | MAPT (0.53) | MAPTSMN1; SMN2SREBF1VDRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6538145-B2 | Having a hydroxy group at 24-position and, optionally, a substituent at 2 beta position; reacting intermediates of the A ring part and intermediates of the C ring; cyclization; coupling; control of calcium metabolism; antitumor agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-25 | — | — | US | disclosed |
| US-20020094972-A1 | 24-hydroxy vitamin D derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094972-A1 | 24-hydroxy vitamin D derivatives | CYP24A1, VDR, CYP2R1 | MAPT 4520/4885SMN1; SMN2 3978/4885SREBF1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.